IS2529B - Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar - Google Patents

Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar

Info

Publication number
IS2529B
IS2529B IS6934A IS6934A IS2529B IS 2529 B IS2529 B IS 2529B IS 6934 A IS6934 A IS 6934A IS 6934 A IS6934 A IS 6934A IS 2529 B IS2529 B IS 2529B
Authority
IS
Iceland
Prior art keywords
spirotycyclic
phosphodiesterase
inhibitors
derivatives
new
Prior art date
Application number
IS6934A
Other languages
English (en)
Other versions
IS6934A (is
Inventor
Edwige Lorthiois
Fabrice Vergne
Patrick Bernardelli
Pierre Ducrot
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8164349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2529(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IS6934A publication Critical patent/IS6934A/is
Publication of IS2529B publication Critical patent/IS2529B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
IS6934A 2001-03-21 2003-08-29 Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar IS2529B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2001/003355 WO2002076953A1 (en) 2001-03-21 2001-03-21 New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
PCT/EP2002/003594 WO2002074754A1 (en) 2001-03-21 2002-03-18 New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors

Publications (2)

Publication Number Publication Date
IS6934A IS6934A (is) 2003-08-29
IS2529B true IS2529B (is) 2009-07-15

Family

ID=8164349

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6934A IS2529B (is) 2001-03-21 2003-08-29 Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar

Country Status (47)

Country Link
US (3) US20020198198A1 (is)
EP (2) EP1373224B1 (is)
JP (1) JP4086663B2 (is)
KR (1) KR100617435B1 (is)
CN (1) CN100447136C (is)
AP (1) AP1699A (is)
AR (1) AR033617A1 (is)
AT (1) ATE367381T1 (is)
AU (1) AU2002304800B2 (is)
BG (1) BG108181A (is)
BR (1) BR0208192A (is)
CA (1) CA2441313C (is)
CU (1) CU23218A3 (is)
CY (1) CY1106829T1 (is)
CZ (1) CZ20032451A3 (is)
DE (1) DE60221233T2 (is)
DK (1) DK1373224T3 (is)
EA (1) EA006815B1 (is)
EC (1) ECSP034750A (is)
EE (1) EE200300459A (is)
ES (1) ES2288552T3 (is)
GE (1) GEP20053631B (is)
GT (1) GT200200053A (is)
HK (1) HK1061854A1 (is)
HR (1) HRP20030740A2 (is)
HU (1) HUP0303637A3 (is)
IL (2) IL157659A0 (is)
IS (1) IS2529B (is)
MA (1) MA27001A1 (is)
MX (1) MXPA03008485A (is)
MY (1) MY142045A (is)
NO (1) NO326086B1 (is)
NZ (1) NZ527847A (is)
OA (1) OA12454A (is)
PA (1) PA8541601A1 (is)
PE (1) PE20021010A1 (is)
PL (1) PL367058A1 (is)
PT (1) PT1373224E (is)
RS (1) RS50429B (is)
SI (1) SI1373224T1 (is)
SK (1) SK11562003A3 (is)
SV (1) SV2003000925A (is)
TN (1) TNSN03076A1 (is)
TW (1) TWI267509B (is)
UA (1) UA74243C2 (is)
WO (2) WO2002076953A1 (is)
ZA (1) ZA200306601B (is)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400244A1 (en) * 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
GB0230195D0 (en) * 2002-12-24 2003-02-05 Biofocus Plc Compound Libraries
HUE026904T2 (en) 2003-04-24 2016-08-29 Incyte Holdings Corp Aza-spiroalkane derivatives as inhibitors of metalloproteases
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
EP1656145A1 (en) * 2003-08-12 2006-05-17 F. Hoffmann-La Roche Ag Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists
CN1976938B (zh) 2004-07-01 2012-08-15 第一三共株式会社 具有pde7抑制活性的噻吩并吡唑衍生物
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
RU2007132865A (ru) * 2005-03-01 2009-03-10 Пфайзер Лимитед (GB) Применение ингибиторов pde7 для лечения невропатической боли
GB0504209D0 (en) * 2005-03-01 2005-04-06 Pfizer Ltd New use of PDE7 inhibitors
KR100680497B1 (ko) * 2005-07-25 2007-02-08 엘지전자 주식회사 근거리통신 시스템에서 단말기가 액세스 포인트에 접속하는방법
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
MEP0408A (xx) 2005-12-02 2010-02-10 Pfizer Ltd Derivati hinociklicnog hinazolina kao inhibitori pde7
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
US7998971B2 (en) * 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
ES2533206T3 (es) * 2007-03-27 2015-04-08 Omeros Corporation Inhibidores de PDE7 para uso en el tratamiento de trastornos del movimiento
EP2160381A2 (en) * 2007-05-24 2010-03-10 Pfizer Limited Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CN103547267A (zh) 2010-11-08 2014-01-29 奥默罗斯公司 使用pde7抑制剂治疗成瘾和冲动控制障碍
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PE20152033A1 (es) 2013-04-19 2016-01-21 Incyte Holdings Corp Heterociclos bicicliclos como inhibidores de fgfr
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
DK3395817T3 (da) * 2015-12-16 2022-03-21 Chia Tai Tianqing Pharmaceutical Group Co Ltd Pyrido[1,2-a]pyrimidonanalog, krystalform deraf, mellemprodukt deraf og fremgangsmåde til fremstilling deraf
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107382976A (zh) * 2017-07-04 2017-11-24 孙秀芹 一种治疗盆腔炎的化合物及制备方法和应用
US11685745B2 (en) 2017-07-12 2023-06-27 Dart Neuroscience, Llc Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
CN112867716A (zh) 2018-05-04 2021-05-28 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815979A (ja) 1981-07-11 1983-01-29 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体およびその製造法
US4764512A (en) 1986-08-27 1988-08-16 Rorer Pharmaceutical Corporation Benzodiazinone-pyridone compounds, cardiotonic compositions including the same, and their uses
GR1000821B (el) * 1988-11-22 1993-01-25 Tanabe Seiyaku Co Μεθοδος παραγωγης παραγωγων κιναζολινονης.
HUT72076A (en) 1992-12-11 1996-03-28 Merck & Co Inc Process for preparing spiro piperidines and homologs which promote release of growth hormone and pharmaceutical compositions containing them
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
US5602143A (en) * 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
NZ319673A (en) * 1995-10-17 2000-06-23 Astra Pharma Prod Quinazoline compounds for inflammatory disorders such rheumatoid arthritis or osteoarthritis
CN1205008A (zh) * 1996-08-30 1999-01-13 协和发酵工业株式会社 咪唑并喹唑啉衍生物
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
WO2000066560A1 (en) * 1999-05-04 2000-11-09 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
SI1173210T1 (en) 1999-05-04 2005-02-28 Wyeth Contraceptive compositions containing antiprogestinic and progestinic
WO2001045707A1 (en) 1999-12-21 2001-06-28 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors

Also Published As

Publication number Publication date
EP1373224A1 (en) 2004-01-02
EE200300459A (et) 2004-02-16
US7214676B2 (en) 2007-05-08
CN1498212A (zh) 2004-05-19
KR20030086315A (ko) 2003-11-07
DK1373224T3 (da) 2007-10-15
GT200200053A (es) 2003-02-12
EP1801106A3 (en) 2007-07-04
SI1373224T1 (sl) 2007-10-31
WO2002076953A1 (en) 2002-10-03
OA12454A (en) 2004-09-30
NO20034187L (no) 2003-10-15
TNSN03076A1 (en) 2005-12-23
AP1699A (en) 2006-12-26
US20040214843A1 (en) 2004-10-28
US20070049558A1 (en) 2007-03-01
MXPA03008485A (es) 2003-12-08
PL367058A1 (en) 2005-02-21
JP2004529123A (ja) 2004-09-24
PT1373224E (pt) 2007-09-25
ZA200306601B (en) 2004-08-25
AU2002304800B2 (en) 2007-08-30
IL157659A (en) 2008-08-07
DE60221233T2 (de) 2008-04-03
NZ527847A (en) 2005-06-24
RS50429B (sr) 2009-12-31
YU74003A (sh) 2006-05-25
BG108181A (en) 2004-09-30
AR033617A1 (es) 2003-12-26
MY142045A (en) 2010-08-30
DE60221233D1 (de) 2007-08-30
AP2003002857A0 (en) 2003-09-30
EA006815B1 (ru) 2006-04-28
IS6934A (is) 2003-08-29
NO326086B1 (no) 2008-09-15
CN100447136C (zh) 2008-12-31
CY1106829T1 (el) 2012-05-23
US20020198198A1 (en) 2002-12-26
PA8541601A1 (es) 2003-05-14
HK1061854A1 (en) 2004-10-08
EA200300906A1 (ru) 2004-02-26
CA2441313C (en) 2009-03-31
CA2441313A1 (en) 2002-09-26
ECSP034750A (es) 2003-10-28
KR100617435B1 (ko) 2006-08-31
JP4086663B2 (ja) 2008-05-14
NO20034187D0 (no) 2003-09-19
CZ20032451A3 (cs) 2004-09-15
MA27001A1 (fr) 2004-12-20
CU23218A3 (es) 2007-07-20
IL157659A0 (en) 2004-03-28
HUP0303637A2 (hu) 2004-03-01
ES2288552T3 (es) 2008-01-16
HUP0303637A3 (en) 2004-07-28
BR0208192A (pt) 2004-03-02
ATE367381T1 (de) 2007-08-15
EP1373224B1 (en) 2007-07-18
SK11562003A3 (sk) 2005-01-03
SV2003000925A (es) 2003-05-20
EP1801106A2 (en) 2007-06-27
WO2002074754A1 (en) 2002-09-26
HRP20030740A2 (en) 2005-06-30
TWI267509B (en) 2006-12-01
PE20021010A1 (es) 2003-02-01
UA74243C2 (uk) 2005-11-15
GEP20053631B (en) 2005-10-10

Similar Documents

Publication Publication Date Title
IS2529B (is) Nýjar spírótrísýklískar afleiður og notkun þeirra sem fosfódíesterasa-7-hindrar
IS6656A (is) Útskiptar kínasólínafleiður og notkun þeirra sem hemla
IS7792A (is) Hýdantóínafleiður og notkun þeirra sem TACE hemla
IS7700A (is) Ný spíróþétt kínasólínón og notkun þeirra sem fosfórdíesterasa hindrar
IS7434A (is) N-amínóasetýl-pýrrólídín-2-karbónítríl og notkun þeirra sem DDP-IV tálma
ZA200500680B (en) Quinoline derivatives and their use as mycrobacterial inhibitors
IS8394A (is) 2-pýridónafleiður sem daukyrningselastasatálmar og notkun þeirra
IS8381A (is) 2-pýridónafleiður sem daufkyrningselastasatálmar og notkun þeirra
NO20032668L (no) Gyraseinhibitorer og anvendelser derav
DK2305250T3 (da) Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer
DK1251848T3 (da) Gyraseinhibitorer og anvendelse deraf
DE60234125D1 (de) E inhibitoren
IS7376A (is) N-arýl-2-oxasólidínón-5-karboxamið og afleiður þeirra og notkun þeirra sem bakteríueyðandi efni
NO20042229L (no) Type 4-fosfodiestemseinhibitorer og anvendelse derav
NO20041272L (no) Tetracycline derivatives and methods of use thereof
AU2002361861A8 (en) Selective 11beta-hsd inhibitors and methods for use thereof
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
IS2773B (is) Amínókínólínafleiður og notkun þeirra sem adenósín A3-bindlar
AU5693101A (en) New thiochromane derivatives and their use as thrombin inhibitors
NO20055668D0 (no) Beta-amyloidinhibitorer og anvendelse derav
IS7334A (is) Bensóþíasól- og bensoxasól-4,7-díonafleiður og notkun þeirra sem cdc25 fosfatasatálma
AU2003218715A8 (en) Azepane derivatives and their use as atk1 inhibitors
ATE299873T1 (de) Substituierte c-furan-2-yl-methylamin- und c- thiophen-2-yl-methylamin-derivate